New CMS program · July 1, 2026 – December 31, 2027
How the Medicare GLP-1 Bridge works
For the first time, Medicare is opening a door to GLP-1 medications for weight loss. The Bridge is a short-term CMS demonstration that covers brand-name Wegovy, Zepbound (KwikPen), and Foundayo for weight management — outside your regular Part D plan, for a fixed $50 monthly copay. Here's the whole process, start to finish.
Why this program exists
Medicare has historically not covered medications for weight loss. That left people choosing between roughly $350–$500 a month at self-pay programs like LillyDirect and NovoCare, compounded versions of uncertain quality, or going without. The Bridge changes that math for people who meet the published criteria — but it runs on its own track, with its own rules, which is exactly why a little preparation goes a long way.
The process, step by step
You and your doctor decide it's appropriate
Your clinician confirms the criteria fit what's in your chart — BMI at the time therapy starts, qualifying conditions, and no exclusions — and decides a GLP-1 is medically right for you. Our free screener helps you arrive at that conversation organized.
Your doctor sends a specially marked prescription
The prescription needs a specific obesity diagnosis code and a pharmacy-routing note so the pharmacy routes the claim to the Bridge instead of your Part D plan. This step is where new-program requests most often stumble — our packet gives your doctor these exact instructions.
Prior authorization, then your fill
The Bridge asks your doctor to complete a prior authorization (the pharmacy sends it, usually within 24–72 hours). Decisions come back within about 72 hours. After the first approved fill, refills don't need a new authorization unless you switch medications, and because approval is based on the eligibility criteria rather than a specific dose, the published rules don't require titrating to a maximum dose to stay covered.
What it covers
- Wegovy — injection and tablets
- Zepbound — KwikPen only (single-dose pens and vials are not covered)
- Foundayo — tablets
- 28- or 30-day fills
What you'll pay
The Bridge copay is $50 for a one-month supply — the same whether you choose Wegovy, the Zepbound KwikPen, or Foundayo. Two details make that number better than it first looks: per CMS, the $50 does not count toward your Part D deductible, and it does not count toward the annual $2,100 out-of-pocket cap. In other words, it sits outside your normal Part D math entirely. (Source: CMS.) Set against the roughly $350–$500 a month many people pay at self-pay programs today, that's the whole point of the program.
Who it's for — the short version
Adults 18+ with Medicare drug coverage, seeking the medication for weight reduction or maintenance, who met a BMI pathway when starting therapy: BMI 35+, BMI 30+ with certain conditions, or BMI 27+ with certain risk conditions. People with type 2 diabetes, moderate-to-severe sleep apnea, or MASH route through their regular Part D plan instead — as do people whose Part D plan paid for a GLP-1 during 2026 (per CMS's June 2026 FAQ; a plan-paid GLP-1 from an earlier year doesn't count). Paying cash through LillyDirect, NovoCare, or a compounding pharmacy does not count against you. Full details in plain English on the criteria page.
Why requests stall — and how to avoid it
Because the Bridge is brand new, the delays people run into usually aren't about whether they qualify — they're about mechanics the clinic is seeing for the first time. The three most common snags:
- Missing the routing note. Without the obesity diagnosis code and the "send to Bridge" instruction, the pharmacy runs the claim through regular Part D, where it's denied. The fix is making sure that note is on the prescription from the start.
- Wrong formulation. A Zepbound prescription written for vials or single-dose pens won't be covered — it has to be the KwikPen. Wegovy and Foundayo don't have this catch.
- The starting-BMI number. If you're already on a GLP-1, the criteria look at your BMI when therapy began, not today's. Bring that number so your doctor isn't guessing.
Walking in with these three handled is the difference between a quick approval and weeks of back-and-forth — which is exactly what the doctor packet is built to prevent.
What this site does and doesn't do
GLP-1 Bridge Help is an independent educational tool. We compare your answers to the published criteria and help you prepare — we don't prescribe, determine eligibility, submit prior authorizations, or guarantee coverage. Those decisions belong to your clinician and the program.
Frequently asked questions
How much does the Medicare GLP-1 Bridge cost?
$50 for a one-month supply, and per CMS it doesn't count toward your Part D deductible or the $2,100 annual out-of-pocket cap.
Do I sign up on a website?
No — there's no website enrollment. The path runs through your doctor, the pharmacy, and the Bridge program. This site only helps you prepare.
How long does approval take?
The pharmacy submits the prior authorization, and decisions typically come back within about 72 hours. Refills after the first approved fill generally don't need a new authorization unless you switch medications.
Which medications are covered?
Wegovy (all formulations), the Foundayo oral pill, and the Zepbound KwikPen. Ozempic and other GLP-1s are not part of the Bridge.
Do I have to reach the highest dose to keep coverage?
Based on the published program materials, no — the Bridge authorization is based on the eligibility criteria (the BMI tiers), not on reaching a specific dose, and refills continue through 2027 without re-authorization unless you switch medications. So unlike some plans' step-therapy rules, the published Bridge rules don't appear to require a maximum dose. Confirm specifics against current CMS materials.
Sources and review status: Content reviewed June 27, 2026, based on published CMS materials including the prescriber fact sheet (CMS Product No. 12235). Check current CMS Medicare GLP-1 Bridge materials before relying on this information: CMS Bridge overview, beneficiary fact sheet (PDF), provider information.